SOLIGENIX, INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
SOLIGENIX, INC. (SNGX) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $46.41 thousand as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-31
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $46.41K.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $4.39K.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $19.54K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $46.41K 10-K · filed 2026-03-31 |
| 2024-12-31 | $4.39K 10-K · filed 2025-03-21 |
| 2023-12-31 | $19.54K 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |